Not Signed In - [ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Drug Safety |
|
|
Clinical Trial: Drug Interaction Study with NS2359 and Cocaine in Cocaine Experienced Volunteers - 1
This study is no longer recruiting patients.
Purpose
The purpose of this study is to conduct a drug interaction study with NS2359 and cocaine in cocaine experienced volunteers.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Cocaine-Related Disorders Drug Administration Schedule Infusions, Intravenous | Drug: NS2359 | Phase I |
MedlinePlus related topics: Cocaine Abuse
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control
Official Title: Drug Interaction Study with NS2359 and Cocaine in Cocaine Experienced Volunteers
Expected Total Enrollment: 24
Study start: June 2001; Study completion: December 2002
This is a single-center, double-blind, placebo-controlled, randomized, single dose, fixed order, dose escalating inpatient design that will study oral NS2359 in cocaine experienced volunteers.
Eligibility
Ages Eligible for Study: 18 Years - 45 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Male or Female, 18-45 yrs of age; females of child-bearing potential using appropriate method of birth control; be able to understand the procedure and agrees to participate via informed consent; must be cocaine dependent according to DSM-4 criteria; must be capable of providing written consent; must be able to comply with protocol requirement, CPU rules and regulations; must not be currently seeking treatment for cocaine abuse.
Exclusion Criteria:
Incapable of understanding the informed consent process; Additional criteria available during screening at the site.
Location Information
Maryland
Uniformed Services University of Health Science, Bethesda, Maryland, 20814 4799, United States
Louis Cantilena, M.D., Principal Investigator, Uniformed Services University of Health Science
More Information
Record last reviewed: April 2004
Last Updated: February 16, 2005
Record first received: April 5, 2002
ClinicalTrials.gov Identifier: NCT00032916
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
